Response to dabrafenib and trametinib combined with pembrolizumab in an elderly patient with lung adenocarcinoma of unknown primary harboring BRAF V600E mutation and high PD-L1 expression: a case report.

Nan Li, Jing Hu, Guangjin Bao, Zhigang Cai

Abstract readCase Reports

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nan LiDepartment of Cardiothoracic Surgery, Naval Medical Center, Naval Medical University, Shanghai, China.

Jing HuDepartment of Cardiothoracic Surgery, Naval Medical Center, Naval Medical University, Shanghai, China.

Guangjin BaoDepartment of Radiology, Naval Medical Center, Naval Medical University, Shanghai, China.

Zhigang CaiDepartment of Cardiothoracic Surgery, Naval Medical Center, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF V600E mutation defines a rare but targetable subset of NSCLC. We report a 70-year-old non-smoking woman with unknown primary lung adenocarcinoma presenting with multistation mediastinal lymph-node metastases and massive malignant pleural and pericardial effusions. Molecular profiling showed BRAF V600E mutation and high PD-L1 expression(TPS 90%, CPS 95). The patient received combined dabrafenib, trametinib, and pembrolizumab with close safety monitoring, achieving rapid tumor control and complete remission by six months with manageable toxicity. This case suggests that early integration of PD-1 blockade with BRAF/MEK inhibition treatment may benefit selected patients and underscores the value of comprehensive molecular and immunohistochemical assessment to guide individualized therapy.

Indexed as

Adenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenLung NeoplasmsMutationNeoplasms, Unknown PrimaryProto-Oncogene Proteins B-rafAgedAntibodies, Monoclonal, HumanizedFemaleHumansImidazolesOximesPyridonesPyrimidinonesTreatment OutcomeAntibodies, Monoclonal, HumanizedB7-H1 AntigenBRAF protein, humanCD274 protein, humandabrafenibImidazolesOximespembrolizumabProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF V600E mutationcase reportdabrafenibimmunotherapynon-small cell lung cancertargeted therapytrametinib

Identifiers

PMID41333480

DOI10.3389/fimmu.2025.1666461

PMCPMC12665787

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.